DGKA and glioblastoma: Though initial studies of anti-PD1 antibodies in patients with GBM were disappointing, there have been signs of activity in small studies of neoadjuvant anti-PD1 [60,61]; boosting T cell activity further with the addition of DGKα inhibition to neoadjuvant anti-PD1 may thus warrant testing for GBM.